<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="adf9b715-8cef-4a0d-ba30-d948b2b04272"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.<br/>
      <br/>GEMCITABINE injection, for intravenous use <br/>Initial U.S. Approval: 1996
</title>
   <effectiveTime value="20250203"/>
   <setId root="22af3507-4b4f-4cad-9d61-89ffc4aabbc7"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080579617" root="1.3.6.1.4.1.519.1"/>
            <name>Sagent Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="cbfba1c7-a864-4342-bea6-4aa34aba3f1c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241031"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="25021-239" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Gemcitabine</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>gemcitabine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="38" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U347PV74IL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>gemcitabine hydrochloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="B76N6SBZ8R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>gemcitabine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydrochloric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5.26" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="25021-239-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190115"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="26.3" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="25021-239-26" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190115"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="52.6" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="25021-239-52" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190115"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209077" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="3ccb6408-1ba2-4044-8d3c-67f7a45442db"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90.000%" align="left"/>
                           <col width="10.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="bottom">Warnings and Precautions, <br/>Severe Cutaneous Adverse Reactions (<linkHtml href="#e30">5.3</linkHtml>)
</td>
                                 <td align="right" valign="bottom">5/2024
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="eab72345-37bd-4c96-ba36-27b67b95efed"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <effectiveTime value="20190904"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Gemcitabine Injection is a nucleoside metabolic inhibitor indicated:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. (<linkHtml href="#s3">1.1</linkHtml>)
</item>
                           <item>in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. (<linkHtml href="#s4">1.2</linkHtml>)
</item>
                           <item>in combination with cisplatin for the treatment of non-small cell lung cancer. (<linkHtml href="#s5">1.3</linkHtml>)
</item>
                           <item>as a single agent for the treatment of pancreatic cancer. (<linkHtml href="#s6">1.4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="48fde103-7cd6-4b96-8070-1deeef63dcd7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Ovarian Cancer
</title>
                     <text>
                        <paragraph>Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="552d66a9-4cce-4ce5-8bcf-53cbd3b5a35b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Breast Cancer
</title>
                     <text>
                        <paragraph>Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="a537e584-408b-4045-9d75-495e9f086a4f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Non-Small Cell Lung Cancer
</title>
                     <text>
                        <paragraph>Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="43e710ca-27f0-460c-970e-195fe236ac13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Pancreatic Cancer
</title>
                     <text>
                        <paragraph>Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="54669194-6ff2-4f29-b47f-56020fc61e0e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Gemcitabine injection is for intravenous use only.
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Ovarian Cancer: 1,000 mg/m<sup>2</sup> over 30 minutes on Days 1 and 8 of each 21-day cycle. (<linkHtml href="#s8">2.1</linkHtml>)
</item>
                           <item>Breast Cancer: 1,250 mg/m<sup>2</sup> over 30 minutes on Days 1 and 8 of each 21-day cycle. (<linkHtml href="#s11">2.2</linkHtml>)
</item>
                           <item>Non-Small Cell Lung Cancer: 1,000 mg/m<sup>2</sup> over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1,250 mg/m<sup>2</sup> over 30 minutes on Days 1 and 8 of each 21-day cycle. (<linkHtml href="#s14">2.3</linkHtml>)
</item>
                           <item>Pancreatic Cancer: 1,000 mg/m<sup>2</sup> over 30 minutes once weekly for the first 7 weeks, then one-week rest, then once weekly for 3 weeks of each 28-day cycle. (<linkHtml href="#s19">2.4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8">
                     <id root="b9e630e3-8534-4cc0-8afe-6f480ba95582"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Ovarian Cancer
</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s9">
                           <id root="f16b7172-8469-45dd-aa4f-6c94ac095e5f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Dose and Schedule</content>
                              </paragraph>
                              <paragraph>The recommended dosage of gemcitabine injection is 1,000 mg/m<sup>2</sup> intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 administered intravenously on Day 1 after gemcitabine injection administration. Refer to carboplatin prescribing information for additional information.
</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s10">
                           <id root="eeac56ca-16f6-410e-bfbb-41631b8e3d0b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Modifications</content>
                              </paragraph>
                              <paragraph>Recommended dosage modifications for gemcitabine injection for myelosuppression are described in <linkHtml href="#t1">Tables 1</linkHtml> and <linkHtml href="#t2">2
</linkHtml>
                                 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.2</linkHtml>)]</content>. Refer to the recommended dosage modifications for non-hematologic adverse reactions <content styleCode="italics">[see
</content>
                                 <content styleCode="italics">Dosage and Administration (<linkHtml href="#s22">2.5</linkHtml>)]</content>.
</paragraph>
                              <table ID="t1" width="100%">
                                 <caption>Table 1: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression on Day of Treatment in Ovarian Cancer
</caption>
                                 <col width="15.900%" align="left"/>
                                 <col width="28.320%" align="left"/>
                                 <col width="5.320%" align="left"/>
                                 <col width="30.980%" align="left"/>
                                 <col width="19.480%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Treatment Day</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Absolute Neutrophil Count</content>
                                          <br/>
                                          <content styleCode="bold">(x 10</content>
                                          <content styleCode="bold">
                                             <sup>6</sup>
                                          </content>
                                          <content styleCode="bold">/L)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Platelet Count</content>
                                          <br/>
                                          <content styleCode="bold">(x 10</content>
                                          <content styleCode="bold">
                                             <sup>6</sup>
                                          </content>
                                          <content styleCode="bold">/L)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Dosage Modification</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td rowspan="2" align="center" valign="top" styleCode="Botrule Lrule Rrule">Day 1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 1,500<br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">And<br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 100,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">None<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 1,500
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 100,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Delay Treatment Cycle
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Lrule Rrule">Day 8
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Greater than or equal to 1,500
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">And
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Greater than or equal to 100,000
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">None
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Lrule Rrule"/>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1,000 to 1,499
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">75,000 to 99,999
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">50% of full dose
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Lrule Rrule"/>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Less than 1,000
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Less than 75,000
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Hold
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t2" width="100%">
                                 <caption>Table 2: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression in Previous Cycle in Ovarian Cancer
</caption>
                                 <col width="28.276%" align="left"/>
                                 <col width="44.281%" align="left"/>
                                 <col width="27.442%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Occurrence</content>
                                       </td>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Myelosuppression During Treatment Cycle</content>
                                       </td>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Dosage Modification</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Initial Occurrence
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">
                                          <list listType="unordered" styleCode="Disc">
                                             <item>Absolute neutrophil count less than 500 x 10<sup>6</sup>/L for more than 5 days or
</item>
                                             <item>Absolute neutrophil count less than 100 x 10<sup>6</sup>/L for more than 3 days or
</item>
                                             <item>Febrile neutropenia or
</item>
                                             <item>Platelets less than 25,000 x 10<sup>6</sup>/L
</item>
                                             <item>Cycle delay for more than one week due to toxicity
</item>
                                          </list>
                                       </td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">Permanently reduce gemcitabine<br/>injection to 800 mg/m<sup>2</sup> on Days 1 and 8
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Subsequent Occurrence
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">If any of the above toxicities occur after the initial dose reduction
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">Permanently reduce gemcitabine injection dose to 800 mg/m<sup>2</sup> on Day 1 only
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="b20b7a83-de24-40da-8e4f-9224b244a164"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Breast Cancer
</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s12">
                           <id root="fb833d58-e86b-4f67-8fef-a593bb10444a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Dose and Schedule</content>
                              </paragraph>
                              <paragraph>The recommended dosage of gemcitabine injection is 1,250 mg/m<sup>2</sup> intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with paclitaxel  175 mg/m<sup>2</sup> administered as a 3-hour intravenous infusion on Day 1 before gemcitabine injection administration. Refer to paclitaxel prescribing information for additional information.
</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s13">
                           <id root="c99f30d2-8895-4d23-8bb2-18e0dc4d2419"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Modifications</content>
                              </paragraph>
                              <paragraph>Recommended dosage modifications for gemcitabine injection for myelosuppression are described in <linkHtml href="#t3">Table 3
</linkHtml>
                                 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.2</linkHtml>)].</content> Refer to the recommended dosage modifications for non-hematologic adverse reactions <content styleCode="italics">[see
</content>
                                 <content styleCode="italics">Dosage and Administration (<linkHtml href="#s22">2.5</linkHtml>)]</content>.
</paragraph>
                              <table ID="t3" width="100%">
                                 <caption>Table 3: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression on Day of Treatment in Breast Cancer
</caption>
                                 <col width="15.937%" align="left"/>
                                 <col width="29.514%" align="left"/>
                                 <col width="6.259%" align="left"/>
                                 <col width="31.294%" align="left"/>
                                 <col width="16.997%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Treatment Day</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Absolute Neutrophil Count</content>
                                          <br/>
                                          <content styleCode="bold">(x 10</content>
                                          <content styleCode="bold">
                                             <sup>6</sup>
                                          </content>
                                          <content styleCode="bold">/L)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Platelet Count</content>
                                          <br/>
                                          <content styleCode="bold">(x 10</content>
                                          <content styleCode="bold">
                                             <sup>6</sup>
                                          </content>
                                          <content styleCode="bold">/L)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Dosage Modification</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td rowspan="2" align="center" valign="top" styleCode="Botrule Lrule Rrule">Day 1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 1,500
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">And<br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 100,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">None<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 1,500
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 100,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Hold
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Lrule Rrule">Day 8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 1,200
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">And
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than 75,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">None
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1,000 to 1,199
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">50,000 to 75,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">75% of full dose
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">700 to 999
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">And
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 50,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">50% of full dose
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 700
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 50,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Hold
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="90cfa9ba-ff74-42b8-afb6-be775e49ed24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Non-Small Cell Lung Cancer
</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s15">
                           <id root="65929863-4e54-4171-8775-acbdf213dd16"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Dose and Schedule</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section ID="s16">
                                 <id root="c1a70bf0-cd96-4de5-94a5-f5a1287b4612"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">28-day schedule</content>
                                    </paragraph>
                                    <paragraph>The recommended dosage of gemcitabine injection is 1,000 mg/m<sup>2</sup> intravenously over 30 minutes on Days 1, 8, and 15 of each 28-day cycle in combination with cisplatin 100 mg/m<sup>2</sup> administered intravenously on Day 1 after gemcitabine injection administration.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s17">
                                 <id root="2b334ad1-123d-4932-ac7b-72ed586b2063"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">21-day schedule</content>
                                    </paragraph>
                                    <paragraph>The recommended dosage of gemcitabine injection is 1,250 mg/m<sup>2</sup> intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with cisplatin 100 mg/m<sup>2</sup> administered intravenously on Day 1 after gemcitabine injection administration.
</paragraph>
                                    <paragraph>Refer to cisplatin prescribing information for additional information.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s18">
                           <id root="dff1176f-ec42-4418-91e8-b34b3d290535"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Modifications</content>
                              </paragraph>
                              <paragraph>Recommended dosage modifications for gemcitabine injection myelosuppression are described in <linkHtml href="#t4">Table 4
</linkHtml>
                                 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.2</linkHtml>)]</content>. Refer to the recommended dosage modifications for non-hematologic adverse reactions <content styleCode="italics">[see
</content>
                                 <content styleCode="italics">Dosage and Administration (<linkHtml href="#s22">2.5</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="81715976-758a-44c8-968c-f508a13e9d70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Pancreatic Cancer
</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s20">
                           <id root="56d7367f-e0c7-4832-a6e9-1263a7f87417"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Dose and Schedule</content>
                              </paragraph>
                              <paragraph>The recommended dosage of gemcitabine injection is 1,000 mg/m<sup>2</sup> intravenously over 30 minutes. The recommended treatment schedule is as follows:
</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Weeks 1 to 8: weekly dosing for the first 7 weeks followed by one-week rest.
</item>
                                 <item>After week 8: weekly dosing on Days 1, 8, and 15 of each 28-day cycle.
</item>
                              </list>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s21">
                           <id root="80bb57e5-37fa-4328-9cce-f9068d82b79a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Modifications</content>
                              </paragraph>
                              <paragraph>Recommended dosage modifications for Gemcitabine Injection for myelosuppression are described in <linkHtml href="#t4">Table 4
</linkHtml>
                                 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.2</linkHtml>)]</content>. Refer to the recommended dosage modifications for non-hematologic adverse reactions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s22">2.5</linkHtml>)]</content>.
</paragraph>
                              <table ID="t4" width="100%">
                                 <caption>Table 4: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression in Pancreatic Cancer and Non-Small Cell Lung Cancer
</caption>
                                 <col width="32.575%" align="left"/>
                                 <col width="8.900%" align="left"/>
                                 <col width="33.525%" align="left"/>
                                 <col width="25.000%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Absolute Neutrophil Count</content>
                                          <br/>
                                          <content styleCode="bold">(x 10</content>
                                          <content styleCode="bold">
                                             <sup>6</sup>
                                          </content>
                                          <content styleCode="bold">/L)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Platelet Count</content>
                                          <br/>
                                          <content styleCode="bold">(x 10</content>
                                          <content styleCode="bold">
                                             <sup>6</sup>
                                          </content>
                                          <content styleCode="bold">/L)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Dosage Modification</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Lrule Rrule">Greater than or equal to 1,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">And
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Greater than or equal to 100,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">None
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Lrule Rrule">500 to 999
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">50,000 to 99,999
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">75% of full dose
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Lrule Rrule">Less than 500
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Or
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Less than 50,000
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">Hold
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="13812b55-b52a-4dba-9356-9a00b7ba1281"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications for Non-Hematologic Adverse Reactions
</title>
                     <text>
                        <paragraph>Permanently discontinue gemcitabine injection for any of the following:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange"/>Severe Cutaneous Adverse Reactions (SCARs) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#e30">5.3</linkHtml>)]</content>
                           </item>
                           <item>
                              <content styleCode="xmChange"/>Unexplained dyspnea or evidence of severe pulmonary toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s30">5.4</linkHtml>)]</content>
                           </item>
                           <item>
                              <content styleCode="xmChange"/>Hemolytic uremic syndrome (HUS) or severe renal impairment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s31">5.5</linkHtml>)]</content>
                           </item>
                           <item>
                              <content styleCode="xmChange"/>Severe hepatic toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s32">5.6</linkHtml>)]</content>
                           </item>
                           <item>
                              <content styleCode="xmChange"/>Capillary leak syndrome (CLS) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s37">5.9</linkHtml>)]</content>
                           </item>
                           <item>
                              <content styleCode="xmChange"/>Posterior reversible encephalopathy syndrome (PRES) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s38">5.10</linkHtml>)]</content>
                           </item>
                        </list>
                        <paragraph>Withhold gemcitabine injection or reduce dose by 50% for other Grade 3 or 4 non-hematological adverse reactions until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="ac2461a6-9f35-4da2-aed9-6a3e215f9060"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Preparation
</title>
                     <text>
                        <paragraph>Gemcitabine injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.<sup>1</sup> Exercise caution and wear gloves when preparing gemcitabine injection solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if gemcitabine injection contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                     <component>
                        <section ID="s24">
                           <id root="e457f88a-378e-4a27-9133-a7207b4ea637"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation for Intravenous Infusion Administration</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Withdraw the calculated dose from the vial and discard any unused portion.
</item>
                                 <item>Prior to administration, dilute the appropriate amount of drug with 0.9% Sodium Chloride Injection to a minimum final concentration of at least 0.1 mg per mL.
</item>
                                 <item>Store diluted gemcitabine injection solution for no more than 24 hours at controlled room temperature of 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Discard if not used within 24 hours after dilution.
</item>
                                 <item>Visually inspect for particulate matter or discoloration prior to administration and discard if particulate matter or discoloration is observed.
</item>
                                 <item>No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.
</item>
                              </list>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s25">
               <id root="1cc52858-4a0a-401d-8aef-1ce0d973ec84"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Injection: 200 mg per 5.26 mL (38 mg per mL), 1 gram per 26.3 mL (38 mg per mL), and 2 grams per 52.6 mL (38 mg per mL) as a clear and colorless to light straw-colored solution in a single-dose vial.
</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 200 mg per 5.26 mL (38 mg per mL), 1 gram per 26.3 mL (38 mg per mL), or 2 grams per 52.6 mL (38 mg per mL) in a single-dose vial. (<linkHtml href="#s25">3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="0c8f5881-a78c-46dd-a6de-41c3d898e9e0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>Gemcitabine injection is contraindicated in patients with a known hypersensitivity to gemcitabine. Reactions include anaphylaxis <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s40">6.1</linkHtml>)]</content>.
</paragraph>
               </text>
               <effectiveTime value="20190904"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with a known hypersensitivity to gemcitabine. (<linkHtml href="#s26">4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="3f18c2db-964f-4c26-88cf-c7a51d49a2b1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. (<linkHtml href="#s28">5.1</linkHtml>)
</item>
                           <item>Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression. (<linkHtml href="#s29">5.2</linkHtml>)
</item>
                           <item>Severe Cutaneous Adverse Reactions (SCARs) Permanently discontinue gemcitabine injection if SCARs occur. (<linkHtml href="#e30">5.3</linkHtml>)
</item>
                           <item>Pulmonary Toxicity and Respiratory Failure: Discontinue gemcitabine injection for unexplained dyspnea or other evidence of severe pulmonary toxicity. (<linkHtml href="#s30">5.4</linkHtml>)
</item>
                           <item>Hemolytic Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment. Discontinue gemcitabine for HUS or severe renal impairment. (<linkHtml href="#s31">5.5</linkHtml>)
</item>
                           <item>Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment. Discontinue gemcitabine for severe hepatic toxicity. (<linkHtml href="#s32">5.6</linkHtml>)
</item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Advise females and males of reproductive potential to use effective contraception. (<linkHtml href="#s33">5.7</linkHtml>, <linkHtml href="#s47">8.1</linkHtml>)
</item>
                           <item>Exacerbation of Radiation Therapy Toxicity: May cause severe and life-threatening toxicity when administered during or within 7 days of radiation therapy. (<linkHtml href="#s34">5.8</linkHtml>)
</item>
                           <item>Capillary Leak Syndrome: Discontinue gemcitabine. (<linkHtml href="#s37">5.9</linkHtml>)
</item>
                           <item>Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue gemcitabine. (<linkHtml href="#s38">5.10</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s28">
                     <id root="d4b07257-ed29-46b1-8eed-177ec3158078"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Schedule-Dependent Toxicity
</title>
                     <text>
                        <paragraph>In clinical trials evaluating the maximum tolerated dose of gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of gemcitabine is influenced by the length of the infusion <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s67">12.3</linkHtml>)]</content>. Refer to the recommended gemcitabine dosage <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s8">2.1</linkHtml>, <linkHtml href="#s11">2.2</linkHtml>, <linkHtml href="#s14">2.3</linkHtml>, <linkHtml href="#s19">2.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s29">
                     <id root="858a809b-4f08-4b40-8b11-a025ce36678a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Myelosuppression
</title>
                     <text>
                        <paragraph>Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia, occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs. In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of the 979 patients who received single agent gemcitabine. The frequencies of Grade 3-4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8% to 28%, and 5% to 55%, respectively, in patients receiving gemcitabine in combination with another drug <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s40">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Prior to each dose of gemcitabine, obtain a complete blood count (CBC) with a differential and a platelet count. Modify the dosage as recommended <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s8">2.1</linkHtml>, <linkHtml href="#s11">2.2</linkHtml>, <linkHtml href="#s14">2.3</linkHtml>, <linkHtml href="#s19">2.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="e30">
                     <id root="eb65c490-76f5-41bc-bb02-eaf60a1746ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.3 Severe Cutaneous Adverse Reactions (SCARs)
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with gemcitabine treatment <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s45">6.2</linkHtml>)]</content>. Monitor patients for signs and symptoms of severe cutaneous adverse reactions. Permanently discontinue gemcitabine in patients who develop SCARs.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s30">
                     <id root="6235678d-f775-40ef-805e-6c927256f31b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Pulmonary Toxicity and Respiratory Failure
</title>
                     <text>
                        <paragraph>Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy. The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of gemcitabine <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s40">6.1</linkHtml>, <linkHtml href="#s45">6.2</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Permanently discontinue gemcitabine in patients who develop unexplained dyspnea, with or without bronchospasm, or evidence of severe pulmonary toxicity.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="f05f7027-78b2-46d3-afa5-faa19e435d43"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hemolytic Uremic Syndrome
</title>
                     <text>
                        <paragraph>Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis, can occur with gemcitabine. In clinical trials, HUS occurred in 0.25%  of 2,429 patients. Most fatal cases of renal failure were due to HUS <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s40">6.1</linkHtml>)].</content> Serious cases of thrombotic microangiopathy (TMA) other than HUS have been reported with gemcitabine <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s45">6.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Assess renal function prior to initiation of gemcitabine and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or evidence of renal failure (increased serum creatinine or BUN). Permanently discontinue gemcitabine in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="4c3ebe24-23e7-4511-9226-1aeecacc381c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Hepatic Toxicity
</title>
                     <text>
                        <paragraph>Drug-induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine alone or with other potentially hepatotoxic drugs <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s40">6.1</linkHtml>, <linkHtml href="#s45">6.2</linkHtml>)].</content> Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency.
</paragraph>
                        <paragraph>Assess hepatic function prior to initiation of gemcitabine and periodically during treatment. Permanently discontinue gemcitabine in patients who develop severe hepatic toxicity.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="298b88cc-ea7e-4239-96b3-562c7ab8f7a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Embryo-Fetal Toxicity
</title>
                     <text>
                        <paragraph>Based on animal data and its mechanism of action, gemcitabine can cause fetal harm when administered to a pregnant woman. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.
</paragraph>
                        <paragraph>Advise pregnant women of the potential risk to a fetus.
</paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with gemcitabine and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with gemcitabine and for 3 months following the final dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s47">8.1</linkHtml>, <linkHtml href="#s53">8.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="da4e8e3b-f9ec-4022-99a0-6c2269debaf7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Exacerbation of Radiation Therapy Toxicity
</title>
                     <text>
                        <paragraph>Gemcitabine is not recommended for use in combination with radiation therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s35">
                           <id root="f91f7a99-4df4-43d2-a68b-29232e918a3c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concurrent (given together or ≤7 days apart)</content>
                              </paragraph>
                              <paragraph>Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which gemcitabine was administered at a dose of 1,000 mg/m<sup>2</sup> to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.
</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s36">
                           <id root="ef19316d-1b94-4d34-aed8-f61e39ce6405"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Non-Concurrent (given &gt;7 days apart)</content>
                              </paragraph>
                              <paragraph>Excessive toxicity has not been observed when gemcitabine is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who received gemcitabine after prior radiation.
</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="562aebfb-74d2-49d2-91f8-7e5fb62d5b47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Capillary Leak Syndrome
</title>
                     <text>
                        <paragraph>Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s45">6.2</linkHtml>)]</content>. Permanently discontinue gemcitabine if CLS develops during therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s38">
                     <id root="970af76b-5aef-4ed7-a984-fc88ef23b34f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Posterior Reversible Encephalopathy Syndrome
</title>
                     <text>
                        <paragraph>Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s45">6.2</linkHtml>)]</content>. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI). Permanently discontinue gemcitabine if PRES develops during therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s39">
               <id root="b70b2088-2d32-417d-b501-a4a5e99a0f73"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity <content styleCode="italics">[see Contraindications (<linkHtml href="#s26">4</linkHtml>)]</content>
                     </item>
                     <item>Schedule-Dependent Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s28">5.1</linkHtml>)]</content>
                     </item>
                     <item>Myelosuppression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.2</linkHtml>)]</content>
                     </item>
                     <item>Severe Cutaneous Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#e30">5.3</linkHtml>)]</content>
                     </item>
                     <item>Pulmonary Toxicity and Respiratory Failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s30">5.4</linkHtml>)]</content>
                     </item>
                     <item>Hemolytic Uremic Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s31">5.5</linkHtml>)]</content>
                     </item>
                     <item>Hepatic Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s32">5.6</linkHtml>)]</content>
                     </item>
                     <item>Exacerbation of Radiation Therapy Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s34">5.8</linkHtml>)]</content>
                     </item>
                     <item>Capillary Leak Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s37">5.9</linkHtml>)]</content>
                     </item>
                     <item>Posterior Reversible Encephalopathy Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s38">5.10</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions for the single agent (≥20%) are nausea/vomiting, anemia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. (<linkHtml href="#s40">6.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold underline">www.fda.gov/medwatch</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s40">
                     <id root="29525af0-6ccc-4e88-aaaf-928c4438dc61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                     </text>
                     <effectiveTime value="20200921"/>
                     <component>
                        <section ID="s41">
                           <id root="c10c37ef-6c98-48da-8cd5-da93983c81b0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Single Agent</content>
                              </paragraph>
                              <paragraph>The data described below reflect exposure to gemcitabine as a single agent administered at doses between 800 mg/m<sup>2</sup> to 1,250 mg/m<sup>2</sup> intravenously over 30 minutes once weekly, in 979 patients with various malignancies. The most common (≥20%) adverse reactions of single agent gemcitabine are nausea/vomiting, anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (≥5%) Grade 3 or 4 adverse reactions were neutropenia, nausea/vomiting, increased ALT, increased alkaline phosphatase, anemia, increased AST, and thrombocytopenia. Approximately 10% of the 979 patients discontinued gemcitabine due to adverse reactions. Adverse reactions resulting in discontinuation of gemcitabine in 2% of 979 patients were cardiovascular adverse reactions (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of gemcitabine in &lt;1% of 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema.
</paragraph>
                              <paragraph>
                                 <linkHtml href="#t5">Tables 5</linkHtml> and <linkHtml href="#t6">6</linkHtml> present the incidence of selected adverse reactions and laboratory abnormalities reported in patients with various malignancies receiving single agent gemcitabine across 5 clinical trials. Additional clinically significant adverse reactions are provided following <linkHtml href="#t6">Table 6</linkHtml>.
</paragraph>
                              <table ID="t5" width="100%">
                                 <caption>Table 5: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Single Agent Gemcitabine<sup>a</sup>
                                 </caption>
                                 <col width="33.925%" align="left"/>
                                 <col width="23.475%" align="left"/>
                                 <col width="22.600%" align="left"/>
                                 <col width="20.000%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on criteria from the World Health Organization (WHO).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> For approximately 60% of patients, non-laboratory adverse events were graded only if assessed to be possibly drug-related.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> N=699 to 974; all patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> 
</td>
                                       <td rowspan="2" align="center" valign="top" styleCode="Rrule">
                                          <br/>69
</td>
                                       <td rowspan="2" align="center" valign="top" styleCode="Rrule">
                                          <br/>13
</td>
                                       <td rowspan="2" align="center" valign="top" styleCode="Rrule">
                                          <br/>1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Nausea and Vomiting
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Fever
</td>
                                       <td align="center" valign="top" styleCode="Rrule">41
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Rash
</td>
                                       <td align="center" valign="top" styleCode="Rrule">30
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Dyspnea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">23
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Diarrhea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Hemorrhage
</td>
                                       <td align="center" valign="top" styleCode="Rrule">17
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Infection
</td>
                                       <td align="center" valign="top" styleCode="Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Alopecia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Stomatitis
</td>
                                       <td align="center" valign="top" styleCode="Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Somnolence
</td>
                                       <td align="center" valign="top" styleCode="Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Paresthesias
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t6" width="100%">
                                 <caption>Table 6: Selected Laboratory Abnormalities Occurring in Patients Receiving Single Agent Gemcitabine<sup>a</sup>
                                 </caption>
                                 <col width="33.925%" align="left"/>
                                 <col width="23.475%" align="left"/>
                                 <col width="22.600%" align="left"/>
                                 <col width="20.000%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on criteria from WHO.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Regardless of causality.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> N=699 to 974; all patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Laboratory Abnormality</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Hematologic
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Anemia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">68
</td>
                                       <td align="center" valign="top" styleCode="Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Neutropenia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">63
</td>
                                       <td align="center" valign="top" styleCode="Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Thrombocytopenia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">24
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Hepatic
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Increased ALT
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">68
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased AST
</td>
                                       <td align="center" valign="top" styleCode="Rrule">67
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased Alkaline Phosphatase
</td>
                                       <td align="center" valign="top" styleCode="Rrule">55
</td>
                                       <td align="center" valign="top" styleCode="Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Hyperbilirubinemia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Renal
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Proteinuria
</td>
                                       <td align="center" valign="top" styleCode="Rrule">45
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Hematuria
</td>
                                       <td align="center" valign="top" styleCode="Rrule">35
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased BUN
</td>
                                       <td align="center" valign="top" styleCode="Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Increased Creatinine
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Additional adverse reactions include the following:
</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (&lt;1%)
</item>
                                 <item>Edema: Edema (13%), peripheral edema (20%), generalized edema (&lt;1%)
</item>
                                 <item>Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, insomnia, rhinitis, sweating, and/or malaise (19%)
</item>
                                 <item>Infection: Sepsis (&lt;1%)
</item>
                                 <item>Extravasation: Injection-site reactions (4%)
</item>
                                 <item>Allergic: Bronchospasm (&lt;2%); anaphylactoid reactions
</item>
                              </list>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s42">
                           <id root="d0b4386a-b697-46fe-862f-62a6747b5de5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Ovarian Cancer</content>
                              </paragraph>
                              <paragraph>
                                 <linkHtml href="#t7">Tables 7</linkHtml> and <linkHtml href="#t8">8</linkHtml> present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine/carboplatin arm, reported in a randomized trial (Study 1) of gemcitabine with carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than 6 months following first-line platinum-based chemotherapy <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s81">14.1</linkHtml>)]</content>. Additional clinically significant adverse reactions, occurring in &lt;10% of patients, are provided following <linkHtml href="#t8">Table 8</linkHtml>.
</paragraph>
                              <paragraph>The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0) and discontinuing treatment for adverse reactions (11% versus 10%), were similar between arms. Dose adjustment for gemcitabine occurred in 10% of patients and gemcitabine dose was omitted in 14% of patients in the gemcitabine/carboplatin arm.
</paragraph>
                              <table ID="t7" width="100%">
                                 <caption>Table 7: Adverse Reactions Occurring in &gt;10% of Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1<sup>a</sup>
                                 </caption>
                                 <col width="24.746%" align="left"/>
                                 <col width="12.516%" align="left"/>
                                 <col width="12.559%" align="left"/>
                                 <col width="12.559%" align="left"/>
                                 <col width="12.516%" align="left"/>
                                 <col width="12.516%" align="left"/>
                                 <col width="12.588%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on National Cancer Institute Common Toxicity Criteria (CTC) Version 2.0.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Regardless of causality.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Carboplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=175)</content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Carboplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=174)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Nausea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">69
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">61
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Alopecia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">49
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">17
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Vomiting
</td>
                                       <td align="center" valign="top" styleCode="Rrule">46
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">36
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Constipation
</td>
                                       <td align="center" valign="top" styleCode="Rrule">42
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">37
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Fatigue
</td>
                                       <td align="center" valign="top" styleCode="Rrule">40
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">32
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Diarrhea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">25
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">14
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Stomatitis/Pharyngitis
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">22
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t8" width="100%">
                                 <caption>Table 8: Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1<sup>a</sup>
                                 </caption>
                                 <col width="29.704%" align="left"/>
                                 <col width="12.302%" align="left"/>
                                 <col width="11.430%" align="left"/>
                                 <col width="11.430%" align="left"/>
                                 <col width="13.188%" align="left"/>
                                 <col width="12.302%" align="left"/>
                                 <col width="9.644%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on National Cancer Institute CTC Version 2.0.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Regardless of causality.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Laboratory Abnormality</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Carboplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=175)</content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Carboplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=174)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Hematologic
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Neutropenia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">90
</td>
                                       <td align="center" valign="top" styleCode="Rrule">42
</td>
                                       <td align="center" valign="top" styleCode="Rrule">29
</td>
                                       <td align="center" valign="top" styleCode="Rrule">58
</td>
                                       <td align="center" valign="top" styleCode="Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Anemia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">86
</td>
                                       <td align="center" valign="top" styleCode="Rrule">22
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">75
</td>
                                       <td align="center" valign="top" styleCode="Rrule">9
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Thrombocytopenia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">78
</td>
                                       <td align="center" valign="top" styleCode="Rrule">30
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Rrule">57
</td>
                                       <td align="center" valign="top" styleCode="Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     RBC Transfusion<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">38
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Platelet Transfusion<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Hematopoietic growth factors were administered more frequently in the gemcitabine-containing arm: leukocyte growth factor (24% and 10%) and erythropoiesis-stimulating agent (7% and 3.9%).
</paragraph>
                              <paragraph>The following clinically relevant, Grade 3 and 4 adverse reactions occurred more frequently in the gemcitabine with carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1%), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0).
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s43">
                           <id root="c24673ce-cbd0-4369-83ed-08ecc93fddda"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Breast Cancer</content>
                              </paragraph>
                              <paragraph>
                                 <linkHtml href="#t9">Tables 9</linkHtml> and <linkHtml href="#t10">10</linkHtml> present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine/paclitaxel arm, reported in a randomized trial (Study 2) of gemcitabine with paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neo-adjuvant setting or for whom anthracyclines were contraindicated <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s82">14.2</linkHtml>)]</content>. Additional clinically significant adverse reactions, occurring in &lt;10% of patients, are provided following <linkHtml href="#t10">Table 10</linkHtml>.
</paragraph>
                              <paragraph>The requirement for dose reduction of paclitaxel were higher for patients in the gemcitabine/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (&lt;1%), the proportion of patients discontinuing treatment for adverse reactions (7% versus 5%) and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms.
</paragraph>
                              <table ID="t9" width="100%">
                                 <caption>Table 9: Selected Adverse Reactions Occurring in Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than in Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2<sup>a</sup>
                                 </caption>
                                 <col width="27.282%" align="left"/>
                                 <col width="13.227%" align="left"/>
                                 <col width="10.541%" align="left"/>
                                 <col width="11.441%" align="left"/>
                                 <col width="13.198%" align="left"/>
                                 <col width="12.327%" align="left"/>
                                 <col width="11.984%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on National Cancer Institute CTC Version 2.0.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Non-laboratory events were graded only if assessed to be possibly drug-related.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Paclitaxel</content>
                                          <br/>
                                          <content styleCode="bold">(N=262)</content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Paclitaxel</content>
                                          <br/>
                                          <content styleCode="bold">(N=259)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Alopecia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">90
</td>
                                       <td align="center" valign="top" styleCode="Rrule">14
</td>
                                       <td align="center" valign="top" styleCode="Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Rrule">92
</td>
                                       <td align="center" valign="top" styleCode="Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Neuropathy-Sensory
</td>
                                       <td align="center" valign="top" styleCode="Rrule">64
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">58
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Nausea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">50
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">31
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Fatigue
</td>
                                       <td align="center" valign="top" styleCode="Rrule">40
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">28
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Vomiting
</td>
                                       <td align="center" valign="top" styleCode="Rrule">29
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Diarrhea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">20
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Anorexia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">17
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Neuropathy-Motor
</td>
                                       <td align="center" valign="top" styleCode="Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Stomatitis/Pharyngitis
</td>
                                       <td align="center" valign="top" styleCode="Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Fever
</td>
                                       <td align="center" valign="top" styleCode="Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Rash/Desquamation
</td>
                                       <td align="center" valign="top" styleCode="Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Febrile Neutropenia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t10" width="100%">
                                 <caption>Table 10: Selected Laboratory Abnormalities Occurring in &gt;10% of Patients Receiving Gemcitabine with Paclitaxel and at a Higher Incidence than Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2<sup>a</sup>
                                 </caption>
                                 <col width="27.286%" align="left"/>
                                 <col width="13.229%" align="left"/>
                                 <col width="10.543%" align="left"/>
                                 <col width="11.443%" align="left"/>
                                 <col width="13.200%" align="left"/>
                                 <col width="10.057%" align="left"/>
                                 <col width="14.243%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on National Cancer Institute CTC Version 2.0.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Regardless of causality.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Laboratory Abnormality</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Paclitaxel</content>
                                          <br/>
                                          <content styleCode="bold">(N=262)</content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Paclitaxel</content>
                                          <br/>
                                          <content styleCode="bold">(N=259)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Hematologic
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Anemia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">69
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">51
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Neutropenia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">69
</td>
                                       <td align="center" valign="top" styleCode="Rrule">31
</td>
                                       <td align="center" valign="top" styleCode="Rrule">17
</td>
                                       <td align="center" valign="top" styleCode="Rrule">31
</td>
                                       <td align="center" valign="top" styleCode="Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Rrule">7
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Thrombocytopenia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">26
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Hepatobiliary
</td>
                                       <td align="center" valign="top" styleCode="Rrule">
                                          <br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">
                                          <br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">
                                          <br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">
                                          <br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">
                                          <br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased ALT
</td>
                                       <td align="center" valign="top" styleCode="Rrule">18
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Increased AST
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Clinically relevant Grade 3 or 4 dyspnea occurred with a higher incidence in the gemcitabine with paclitaxel arm compared with the paclitaxel arm (1.9% versus 0).
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s44">
                           <id root="771499a6-f9ce-4108-9e2d-51665288e1a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Non-Small Cell Lung Cancer</content>
                              </paragraph>
                              <paragraph>
                                 <linkHtml href="#t11">Tables 11</linkHtml> and <linkHtml href="#t12">12</linkHtml> present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with cisplatin arm, reported in a randomized trial (Study 3) of gemcitabine with cisplatin (n=260) administered in 28-day cycles as compared to cisplatin alone (n=262) in patients receiving first-line treatment for locally advanced or metastatic NSCLC <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s83">14.3</linkHtml>)]</content>.
</paragraph>
                              <paragraph>Patients randomized to gemcitabine with cisplatin received a median of 4 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. In this trial, the requirement for dose adjustments (&gt;90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving gemcitabine with cisplatin compared to those receiving cisplatin alone. The incidence of febrile neutropenia (3% versus &lt;1%), sepsis (4% versus 1%), Grade 3 cardiac dysrhythmias (3% versus &lt;1%) were all higher in the gemcitabine/cisplatin arm compared to the cisplatin alone arm. The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related deaths, including 3 resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on the cisplatin arm.
</paragraph>
                              <table ID="t11" width="100%">
                                 <caption>Table 11: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3<sup>a</sup>
                                 </caption>
                                 <col width="22.957%" align="left"/>
                                 <col width="13.300%" align="left"/>
                                 <col width="12.414%" align="left"/>
                                 <col width="12.414%" align="left"/>
                                 <col width="14.186%" align="left"/>
                                 <col width="13.986%" align="left"/>
                                 <col width="10.743%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on National Cancer Institute CTC.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Non-laboratory events were graded only if assessed to be possibly drug-related.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> N=217 to 253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> N=213 to 248; all cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>d</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Nausea
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">93
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">25
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
													</td>
                                       <td align="center" valign="middle" styleCode="Rrule">87
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">20
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Vomiting
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">78
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">11
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">12
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">71
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">10
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">9
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Alopecia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">53
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">33
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Neuro Motor
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">35
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">12
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">15
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Diarrhea
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">24
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">13
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Neuro Sensory
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">23
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">18
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Infection
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">18
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">12
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Fever
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">16
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">5
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Neuro Cortical
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">16
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">9
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Neuro Mood
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">16
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">10
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Local
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">15
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">6
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Neuro Headache
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">14
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">7
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Stomatitis
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">14
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">5
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Hemorrhage
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">14
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">4
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">   Hypotension
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">12
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">7
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">   Rash
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">11
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t12" width="100%">
                                 <caption>Table 12: Selected Laboratory Abnormalities Occurring in &gt;10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3<sup>a</sup>
                                 </caption>
                                 <col width="33.738%" align="left"/>
                                 <col width="12.470%" align="left"/>
                                 <col width="9.799%" align="left"/>
                                 <col width="10.684%" align="left"/>
                                 <col width="12.470%" align="left"/>
                                 <col width="10.041%" align="left"/>
                                 <col width="10.798%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on National Cancer Institute CTC.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Regardless of causality.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> N=217 to 253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> N=213 to 248; all cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Laboratory Abnormality</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>d</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">Hematologic
</td>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Anemia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">89
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">22
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">67
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">6
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Thrombocytopenia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">85
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">25
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">25
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">13
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Neutropenia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">79
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">22
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">35
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">20
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Lymphopenia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">75
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">25
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">18
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">51
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">12
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">5
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     RBC Transfusion<sup>e</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Rrule">39
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">-
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">-
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">13
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">-
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Platelet Transfusions<sup>e</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">21
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">&lt;1
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">Hepatic<br/>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Increased Transaminase
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">22
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">10
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Increased Alkaline Phosphatase
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">19
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">Renal
</td>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">Increased Creatinine
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">38
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">4
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">&lt;1
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">31
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">&lt;1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Proteinuria
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">23
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">18
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Hematuria
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">15
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">Other Laboratory
</td>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                       <td align="center" valign="middle" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Hyperglycemia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">30
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">4
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">23
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Lrule Rrule">     Hypomagnesemia
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">30
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">4
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">3
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">17
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Hypocalcemia
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">18
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">&lt;1
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <linkHtml href="#t13">Tables 13</linkHtml> and <linkHtml href="#t14">14</linkHtml> present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with cisplatin arm, reported in a randomized trial (Study 4) of gemcitabine with cisplatin (n=69) administered in 21-day cycles as compared to etoposide with cisplatin (n=66) in patients receiving first-line treatment for locally advanced or metastatic NSCLC <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s83">14.3</linkHtml>)]</content>. Additional clinically significant adverse reactions are provided following <linkHtml href="#t14">Table 14</linkHtml>.
</paragraph>
                              <paragraph>Patients in the gemcitabine/cisplatin (GC) arm received a median of 5 cycles and those in the etoposide/cisplatin (EC) arm received a median of 4 cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the GC arm and 68% in the EC arm. The incidence of hospitalizations for adverse reactions was 22% in the GC arm and 27% in the EC arm. The proportion of patients who discontinued treatment for adverse reactions was higher in the GC arm (14% versus 8%). The proportion of patients who were hospitalized for febrile neutropenia was lower in the GC arm (7% versus 12%). There was one death attributed to treatment, a patient with febrile neutropenia and renal failure, which occurred in the GC arm.
</paragraph>
                              <table ID="t13" width="100%">
                                 <caption>Table 13: Selected Adverse Reactions in Patients Receiving Gemcitabine with Cisplatin in Study 4<sup>a</sup>
                                 </caption>
                                 <col width="32.338%" align="left"/>
                                 <col width="13.170%" align="left"/>
                                 <col width="10.541%" align="left"/>
                                 <col width="10.541%" align="left"/>
                                 <col width="12.298%" align="left"/>
                                 <col width="11.413%" align="left"/>
                                 <col width="9.699%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on criteria from WHO.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> N=67 to 69; all gemcitabine/cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> N=57 to 63; all etoposide/cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Flu-like syndrome and edema were not graded.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Etoposide/Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>d</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Nausea and Vomiting
</td>
                                       <td align="center" valign="top" styleCode="Rrule">96
</td>
                                       <td align="center" valign="top" styleCode="Rrule">35
</td>
                                       <td align="center" valign="top" styleCode="Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Rrule">86
</td>
                                       <td align="center" valign="top" styleCode="Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Rrule">7
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Alopecia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">77
</td>
                                       <td align="center" valign="top" styleCode="Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">92
</td>
                                       <td align="center" valign="top" styleCode="Rrule">51
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Paresthesias
</td>
                                       <td align="center" valign="top" styleCode="Rrule">38
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Infection
</td>
                                       <td align="center" valign="top" styleCode="Rrule">28
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Stomatitis
</td>
                                       <td align="center" valign="top" styleCode="Rrule">20
</td>
                                       <td align="center" valign="top" styleCode="Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">18
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Diarrhea
</td>
                                       <td align="center" valign="top" styleCode="Rrule">14
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Edema<sup>e</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Rash
</td>
                                       <td align="center" valign="top" styleCode="Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Hemorrhage
</td>
                                       <td align="center" valign="top" styleCode="Rrule">9
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Fever
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Somnolence
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule"> Flu-like Syndrome<sup>e</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Dyspnea
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t14" width="100%">
                                 <caption>Table 14: Selected Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Cisplatin in Study 4<sup>a</sup>
                                 </caption>
                                 <col width="32.338%" align="left"/>
                                 <col width="13.170%" align="left"/>
                                 <col width="10.541%" align="left"/>
                                 <col width="10.541%" align="left"/>
                                 <col width="12.298%" align="left"/>
                                 <col width="11.413%" align="left"/>
                                 <col width="9.699%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Grade based on criteria from WHO.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Regardless of causality.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> N=67 to 69; all gemcitabine/cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> N=57 to 63; all etoposide/cisplatin patients with laboratory or non-laboratory data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="7" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Percent of patients receiving transfusions. WHO Grading scale not applicable to proportion patients with transfusions.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Laboratory Abnormality</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Etoposide/Cisplatin</content>
                                          <content styleCode="bold">
                                             <sup>d</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">All Grades</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 3</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grade 4</content>
                                          <br/>
                                          <content styleCode="bold">(%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Hematologic
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Anemia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">88
</td>
                                       <td align="center" valign="top" styleCode="Rrule">22
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">77
</td>
                                       <td align="center" valign="top" styleCode="Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Rrule">2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Neutropenia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">88
</td>
                                       <td align="center" valign="top" styleCode="Rrule">36
</td>
                                       <td align="center" valign="top" styleCode="Rrule">28
</td>
                                       <td align="center" valign="top" styleCode="Rrule">87
</td>
                                       <td align="center" valign="top" styleCode="Rrule">20
</td>
                                       <td align="center" valign="top" styleCode="Rrule">56
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Thrombocytopenia
</td>
                                       <td align="center" valign="top" styleCode="Rrule">81
</td>
                                       <td align="center" valign="top" styleCode="Rrule">39
</td>
                                       <td align="center" valign="top" styleCode="Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Rrule">45
</td>
                                       <td align="center" valign="top" styleCode="Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     RBC Transfusion<sup>e</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">29
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Platelet Transfusion<sup>e</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Hepatic
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased Alkaline Phosphatase
</td>
                                       <td align="center" valign="top" styleCode="Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased ALT
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Increased AST
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Renal
</td>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                       <td align="center" valign="top" styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Hematuria
</td>
                                       <td align="center" valign="top" styleCode="Rrule">22
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Proteinuria
</td>
                                       <td align="center" valign="top" styleCode="Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">     Increased BUN
</td>
                                       <td align="center" valign="top" styleCode="Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Increased Creatinine
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20200921"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s45">
                     <id root="820e7259-be63-4f6f-acdb-f0d37de4924f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience
</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of gemcitabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System:</content> TMA
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular:</content> Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular:</content> Peripheral vasculitis, gangrene, capillary leak syndrome
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="italics">Skin:</content> Cellulitis, pseudocellulitis, severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP); desquamation and bullous skin eruptions
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic:</content> Hepatic failure, hepatic veno-occlusive disease
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pulmonary:</content> Interstitial pneumonitis, pulmonary fibrosis, pulmonary eosinophilia, pulmonary edema, adult respiratory distress syndrome (ARDS)
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> Posterior reversible encephalopathy syndrome (PRES)
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s46">
               <id root="9dd03146-3ef1-4ac5-b2cb-9e821399cf07"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (<linkHtml href="#s51">8.2</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s47">
                     <id root="ea62e8cd-e62e-4121-8ab5-4ea144a01a9b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s48">
                           <id root="f0555a2c-8352-4714-9c3a-5b4a305848d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on animal data and its mechanism of action, gemcitabine can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s66">12.1</linkHtml>)]</content>. There are no available data on the use of gemcitabine in pregnant women. In animal reproduction studies, gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits <content styleCode="italics">(see <linkHtml href="#s49">Data</linkHtml>)</content>. Advise pregnant women of the potential risk to a fetus <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s53">8.3</linkHtml>)]</content>.
</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s49">
                           <id root="6e605df2-60b9-4b73-b38a-61225772cff4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section ID="s50">
                                 <id root="794b1443-b093-4a26-b933-fd6d7b3ab08b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Gemcitabine is embryotoxic in mice. Daily dosing of gemcitabine to pregnant mice increased the incidence of fetal malformations (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day [about 0.005 times the 1,000 mg/m<sup>2</sup> clinical dose based on body surface area (BSA)]. Gemcitabine is embryotoxic and fetotoxic in rabbits. Daily dosing of gemcitabine to pregnant rabbits resulted in fetotoxicity (decreased fetal viability, reduced litter sizes and developmental delays) and increased the incidence of fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day (about 0.002 times the 1,000 mg/m<sup>2</sup> clinical dose based on BSA).
</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s51">
                     <id root="5b75531f-aca9-42c6-a8d6-11345d973b69"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20190904"/>
                     <component>
                        <section ID="s52">
                           <id root="933e4aa7-d6eb-492c-81fb-f0679eb347dd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of gemcitabine or its metabolites in human milk, or their effects on the breastfed infant or on milk production. Due to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with gemcitabine and for at least one week following the last dose.
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s53">
                     <id root="19018183-5471-4125-94d6-259d029b9256"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <effectiveTime value="20190904"/>
                     <component>
                        <section ID="s54">
                           <id root="44565121-f8fe-4a64-86a2-57765c85c2e2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating gemcitabine <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s47">8.1</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s55">
                           <id root="95e8ac3d-abfb-4e1f-b4eb-ffe650a7b294"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Gemcitabine can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s47">8.1</linkHtml>)].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                           <component>
                              <section ID="s56">
                                 <id root="e5b31f26-ac65-4505-8ce2-d70277a65f97"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Because of the potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment with gemcitabine and for 6 months after the final dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s57">
                                 <id root="d3450def-6fae-4fe5-b6a5-b81e5c23583b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with gemcitabine and for 3 months after the final dose <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#s79">13.1</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s58">
                           <id root="a857b8c1-bc3c-4087-9a2f-9f4caf72ef99"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                           <component>
                              <section ID="s59">
                                 <id root="b41fad7a-6469-41c0-b967-3a9f9ad1d3d9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Based on animal studies, gemcitabine may impair fertility in males of reproductive potential <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#s79">13.1</linkHtml>)].</content> It is not known whether these effects on fertility are reversible.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s60">
                     <id root="0839e9c2-31ca-4b59-b391-e95971fe6d8d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of gemcitabine have not been established in pediatric patients.
</paragraph>
                        <paragraph>The safety and pharmacokinetics of gemcitabine were evaluated in a trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m<sup>2</sup>/min for 360 minutes weekly for three weeks followed by a one-week rest period.
</paragraph>
                        <paragraph>The safety and activity of gemcitabine were evaluated in a trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at a dose of 10 mg/m<sup>2</sup>/min administered over 360 minutes weekly for three weeks followed by a one-week rest period. Patients with M1 or M2 bone marrow on Day 28 who did not experience unacceptable toxicity were eligible to receive a maximum of one additional four-week course. Toxicities observed included myelosuppression, febrile neutropenia, increased serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s61">
                     <id root="07718d6a-82cd-4c79-a875-a9f6b6f91e55"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>In clinical studies which enrolled 979 patients with various malignancies who received single agent gemcitabine, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of a higher rate of Grade 3-4 thrombocytopenia in older patients as compared to younger patients.
</paragraph>
                        <paragraph>In a randomized trial in women with ovarian cancer (Study 1), 175 women received gemcitabine with carboplatin, of which 29% were age 65 years or older. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3-4 neutropenia in women 65 years of age or older <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s8">2.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Gemcitabine clearance is affected by age; however, there are no recommended dose adjustments based on patients' age <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s67">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s62">
                     <id root="423b967d-ae7f-4d41-b7be-14486fe0ce8a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Gender
</title>
                     <text>
                        <paragraph>Gemcitabine clearance is decreased in females <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s67">12.3</linkHtml>)].</content> In single agent studies of gemcitabine, women, especially older women, were more likely not to proceed to a subsequent cycle and to experience Grade 3-4 neutropenia and thrombocytopenia <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s8">2.1</linkHtml>, <linkHtml href="#s11">2.2</linkHtml>, <linkHtml href="#s14">2.3</linkHtml>, <linkHtml href="#s19">2.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s63">
               <id root="15b75aeb-f414-4473-b33e-bfd61d6fc918"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <text>
                  <paragraph>There is no known antidote for overdoses of gemcitabine. Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5,700 mg/m<sup>2</sup> was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a dose-escalation study. In the event of suspected overdose, monitor with appropriate blood counts and provide supportive therapy, as necessary.
</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="s64">
               <id root="01f54acc-7b66-4d76-bc99-511b3365a5c0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Gemcitabine is a nucleoside metabolic inhibitor. The chemical name of gemcitabine HCl is 2′-deoxy-2′,2′-difluorocytidine monohydrochloride (β-isomer). The structural formula is as follows:
</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Gemcitabine HCl is a white to off-white solid with a molecular formula of C<sub>9</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub> • HCl and a molecular weight of 299.66 g/mol. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.
</paragraph>
                  <paragraph>Gemcitabine Injection is a sterile solution in single-dose vials for intravenous use. Each vial contains 200 mg, 1 gram, or 2 grams of gemcitabine equivalent to 227.7 mg, 1.138 grams, or 2.276 grams of gemcitabine HCl. Each mL contains 38 mg of gemcitabine free base in Water for Injection, USP equivalent to 43.26 mg of gemcitabine HCl. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="gem0a-0007-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s65">
               <id root="f1f568a3-0ba7-4690-9cc8-6fe88717362a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="s66">
                     <id root="40be4511-8e0c-480d-9189-9836be6718f9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands which eventually results in the initiation of apoptotic cell death.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s67">
                     <id root="70bb39fb-c298-46e6-8036-884b1f77a2f6"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>The pharmacokinetics of gemcitabine were examined in 353 patients, with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (&lt;70 minutes) and long infusions (70 to 285 minutes). The total gemcitabine dose varied from 500 mg/m<sup>2</sup> to 3,600 mg/m<sup>2</sup>.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s68">
                           <id root="502d034f-9393-4bc8-b695-16e4a76fc0bc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m<sup>2</sup> following infusions lasting &lt;70 minutes. For long infusions, the volume of distribution rose to 370 L/m<sup>2</sup>.
</paragraph>
                              <paragraph>Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and sex. Gemcitabine plasma protein binding is negligible.
</paragraph>
                           </text>
                           <effectiveTime value="20190904"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s69">
                           <id root="d7a4d084-60ca-48d8-a1ce-49223991a3dc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section ID="s70">
                                 <id root="1da82193-eb34-44ed-94e5-fcf7fecca27e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s71">
                                 <id root="f403540d-b2d5-43f2-a7ee-ae46050d4386"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Gemcitabine disposition was studied in 5 patients who received a single 1,000 mg/m<sup>2</sup> of radiolabeled drug as a 30-minute infusion. Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (&lt;10%) and the inactive uracil metabolite, 2′-deoxy-2′,2′- difluorouridine (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s72">
                           <id root="2e0cd956-a676-4382-b7fe-360356540bdb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20200921"/>
                           <component>
                              <section ID="s73">
                                 <id root="1fc69937-316a-4f5b-a4e8-539d5ee3e0ba"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>Clearance of gemcitabine was affected by age. The lower clearance in geriatric patients results in higher concentrations of gemcitabine for any given dose. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. <linkHtml href="#t15">Table 15</linkHtml> shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and sex.
</paragraph>
                                    <paragraph>Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and for long infusions varied from 245 to 638 minutes, depending on age and sex, reflecting a greatly increased volume of distribution with longer infusions.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s74">
                                 <id root="6452b7a8-0868-4055-acaa-cb795dd3d108"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Male and Female Patients</content>
                                    </paragraph>
                                    <paragraph>Females have lower clearance and longer half-lives than male patients as described in <linkHtml href="#t15">Table 15</linkHtml>.
</paragraph>
                                    <table ID="t15" width="100%">
                                       <caption>Table 15: Gemcitabine Clearance and Half-Life for the “Typical” Patient
</caption>
                                       <col width="14.680%" align="left"/>
                                       <col width="20.180%" align="left"/>
                                       <col width="23.860%" align="left"/>
                                       <col width="22.940%" align="left"/>
                                       <col width="18.340%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="5" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> Half-life for patients receiving a &lt;70 minute infusion.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                                <content styleCode="bold">Age</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Clearance <br/>Men <br/>(L/hr/m</content>
                                                <content styleCode="bold">
                                                   <sup>2</sup>
                                                </content>
                                                <content styleCode="bold">)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Clearance <br/>Women <br/>(L/hr/m</content>
                                                <content styleCode="bold">
                                                   <sup>2</sup>
                                                </content>
                                                <content styleCode="bold">)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Half-Life</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">Men <br/>(min)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Half-Life</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">Women</content>
                                                <br/>
                                                <content styleCode="bold">(min)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Lrule Rrule">29
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">92.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">69.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">42
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">49
</td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Lrule Rrule">45
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">75.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">57.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">48
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">57
</td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Lrule Rrule">65
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">55.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">41.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">61
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">73
</td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Lrule Rrule">79
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">40.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">30.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">94
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20200921"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s75">
                                 <id root="f2e62204-6163-40f0-9809-64eb5be836d0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>No clinical studies have been conducted with gemcitabine in patients with decreased renal function.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s76">
                                 <id root="5efbcc3f-ea8f-4dde-bbbc-a94661f840ff"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>No clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190904"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s77">
                           <id root="d9827cb6-ff9a-4f4d-a1b2-019c6a516a22"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>When gemcitabine (1,250 mg/m<sup>2</sup> on Days 1 and 8) and cisplatin (75 mg/m<sup>2</sup> on Day 1) were administered in patients with NSCLC, the clearance of gemcitabine on Day 1 was 128 L/hr/m<sup>2</sup> and on Day 8 was 107 L/hr/m<sup>2</sup>. Data from patients with NSCLC demonstrate that gemcitabine and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single agent, however, due to wide confidence intervals and small sample size, interpatient variability may be observed.
</paragraph>
                              <paragraph>Data from patients with metastatic breast cancer shows that gemcitabine has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine.
</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s78">
               <id root="8f15941a-a5a7-4956-992f-5a2a7a94493a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="s79">
                     <id root="ac5a1759-12a2-4e6b-8eb1-ac36b9a9afe8"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>Long-term animal studies to evaluate the carcinogenic potential of gemcitabine have not been conducted. Gemcitabine was mutagenic in an <content styleCode="italics">in vitro</content> mouse lymphoma (L5178Y) assay and was clastogenic in an <content styleCode="italics">in vivo</content> mouse micronucleus assay. Gemcitabine intraperitoneal doses of 0.5 mg/kg/day (about 1/700 the 1,000 mg/m<sup>2</sup> clinical dose based on BSA) in male mice resulted in moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the 1,000 mg/m<sup>2</sup> clinical dose based on BSA) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1,300 the 1,000 mg/m<sup>2</sup> clinical dose based on BSA).
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s80">
               <id root="7c0db8bc-c03e-437f-89f0-ff125e091b98"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="s81">
                     <id root="d41df6b7-5a95-4d47-93ab-7a0ef2ae7c49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Ovarian Cancer
</title>
                     <text>
                        <paragraph>The efficacy of gemcitabine was evaluated in a randomized trial (Study 1) conducted in women with advanced ovarian cancer that had relapsed at least 6 months after first-line platinum-based therapy. Patients were randomized to receive either gemcitabine 1,000 mg/m<sup>2</sup> on Days 1 and 8 of each 21-day cycle with carboplatin AUC 4 on Day 1 after gemcitabine administration (n = 178) or carboplatin AUC 5 on Day 1 of each 21-day cycle (n = 178). The major efficacy outcome measure was progression-free survival (PFS).
</paragraph>
                        <paragraph>A total of 356 patients were enrolled. Demographics and baseline characteristics are shown in <linkHtml href="#t16">Table 16</linkHtml>. Efficacy results are presented in <linkHtml href="#t17">Table 17</linkHtml> and <linkHtml href="#fig1">Figure 1</linkHtml>. The addition of gemcitabine to carboplatin resulted in statistically significant improvements in PFS and overall response rate. Approximately 75% of patients in each arm received additional chemotherapy for disease progression; 13 of 120 patients in the carboplatin alone arm received gemcitabine for treatment of disease progression. There was no significant difference in overall survival between the treatment arms.
</paragraph>
                        <table ID="t16" width="100%">
                           <caption>Table 16: Baseline Demographics and Clinical Characteristics for Study 1
</caption>
                           <col width="43.648%" align="left"/>
                           <col width="28.176%" align="left"/>
                           <col width="28.176%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> 5 patients on gemcitabine/carboplatin arm and 4 patients on carboplatin arm had no baseline Eastern Cooperative Oncology Group (ECOG) performance status.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> 2 patients on gemcitabine/carboplatin arm and 1 patient on carboplatin arm had platinum-free interval &lt;6 months.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Gemcitabine/Carboplatin</content>
                                    <br/>
                                    <content styleCode="bold">(N=178)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Carboplatin</content>
                                    <br/>
                                    <content styleCode="bold">(N=178)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Median age, years
</td>
                                 <td align="center" valign="top" styleCode="Rrule">59
</td>
                                 <td align="center" valign="top" styleCode="Rrule">58
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Range
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">36 to 78
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 to 81
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Baseline ECOG performance status 0 to 1<sup>a</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">94%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">95%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Disease Status
</td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">     Evaluable
</td>
                                 <td align="center" valign="top" styleCode="Rrule">8%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">3%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Bidimensionally measurable
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">92%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">96%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Platinum-free interval<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">     6 to 12 months
</td>
                                 <td align="center" valign="top" styleCode="Rrule">40%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">40%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     &gt;12 months
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">59%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">60%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">First-line therapy
</td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">     Platinum-taxane combination
</td>
                                 <td align="center" valign="top" styleCode="Rrule">70%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">71%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">     Platinum-non-taxane combination
</td>
                                 <td align="center" valign="top" styleCode="Rrule">29%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">28%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Platinum monotherapy
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%
</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t17" width="100%">
                           <caption>Table 17: Efficacy Results in Study 1
</caption>
                           <col width="39.633%" align="left"/>
                           <col width="29.733%" align="left"/>
                           <col width="30.633%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> CI=confidence interval.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> Log rank, unadjusted.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> Chi square.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>d</sup> CR=Complete response.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>e</sup> PR with PRNM=Partial response with partial response, non-measurable disease.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>f</sup> Independently reviewed cohort - gemcitabine/carboplatin (n=121), carboplatin (n=101); independent reviewers unable to measure disease detected by sonography or physical exam.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Gemcitabine/Carboplatin <br/>(N=178)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Carboplatin</content>
                                    <br/>
                                    <content styleCode="bold">(N=178)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Progression-Free Survival</content>
                                    <br/>     Median (95% CI<sup>a</sup>) in months
</td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">8.6 (8.0, 9.7)
</td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">5.8 (5.2, 7.1)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Hazard Ratio (95% CI)
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.72 (0.57, 0.90)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">p=value<sup>b</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.0038
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Overall Survival</content>
                                    <br/>     Median (95% CI) in months
</td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">18.0 (16.2, 20.3)
</td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">17.3 (15.2, 19.3)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Hazard Ratio (95% CI)
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.98 (0.78, 1.24)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">p=value<sup>b</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.8977
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Overall Response Rate by Investigator Review</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">47.2%
</td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">30.9%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">p=value<sup>c</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.0016
</td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">CR<sup>d</sup>
                                    <br/>     PR with PRNM<sup>e</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule">14.6%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">6.2%
</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">32.6%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">24.7%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Overall Response Rate by Independent Review</content>
                                    <content styleCode="bold">
                                       <sup>f</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">46.3%
</td>
                                 <td align="center" valign="bottom" styleCode="Botrule Rrule">35.6%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">p=value<sup>c</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.11
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">     CR<sup>d</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule">9.1%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">4.0%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     PR with PRNM<sup>e</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">37.2%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">31.7%
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="fig1" styleCode="MultiMediaCaption">
                           <content styleCode="bold">Figure 1: Kaplan-Meier Curves for Progression-Free Survival in Study 1</content>
                        </paragraph>
                        <renderMultiMedia ID="f02" referencedObject="mm02"/>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <observationMedia ID="mm02">
                           <text>Figure 1
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="gem0a-0007-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s82">
                     <id root="a79ac30a-e7ea-48e6-af13-d169bb3e228e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Breast Cancer
</title>
                     <text>
                        <paragraph>The efficacy of gemcitabine was evaluated in a multinational, randomized, open-label trial conducted in women receiving initial treatment for metastatic breast cancer and who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated.
</paragraph>
                        <paragraph>Patients were randomized to receive gemcitabine 1,250 mg/m<sup>2</sup> on Days 1 and 8 of each 21-day cycle with paclitaxel 175 mg/m<sup>2</sup> administered on Day 1 before gemcitabine administration (n = 267) or paclitaxel 175 mg/m<sup>2</sup> on Day 1 of each 21-day cycle (n = 262). The major efficacy outcome measure was time to documented disease progression.
</paragraph>
                        <paragraph>A total of 529 patients were enrolled. Demographic and baseline characteristics were similar between treatment arms (<linkHtml href="#t18">Table 18</linkHtml>).
</paragraph>
                        <paragraph>Efficacy results are presented in <linkHtml href="#t19">Table 19</linkHtml> and <linkHtml href="#fig2">Figure 2</linkHtml>. The addition of gemcitabine to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to paclitaxel alone. There was no significant difference in overall survival.
</paragraph>
                        <table ID="t18" width="100%">
                           <caption>Table 18: Baseline Demographics and Clinical Characteristics for Study 2
</caption>
                           <col width="43.119%" align="left"/>
                           <col width="27.524%" align="left"/>
                           <col width="29.357%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> Karnofsky Performance Status.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Gemcitabine/Paclitaxel</content>
                                    <br/>
                                    <content styleCode="bold">(N=267)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Paclitaxel</content>
                                    <br/>
                                    <content styleCode="bold">(N=262)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Median age, years
</td>
                                 <td align="center" valign="top" styleCode="Rrule">53
</td>
                                 <td align="center" valign="top" styleCode="Rrule">52
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Range
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">26 to 83
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">26 to 75
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Metastatic disease
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">97%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">97%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Baseline KPS<sup>a </sup> ≥90
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">70%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">74%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Number of tumor sites <br/>     1 to 2<br/>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule">57%
</td>
                                 <td align="center" valign="bottom" styleCode="Rrule">59%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     ≥3
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">43%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">41%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Visceral disease
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">73%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">73%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Prior anthracycline
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">97%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">96%
</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t19" width="100%">
                           <caption>Table 19: Efficacy Results in Study 2
</caption>
                           <col width="44.033%" align="left"/>
                           <col width="27.533%" align="left"/>
                           <col width="28.433%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> These represent reconciliation of investigator and Independent Review Committee assessments according to a predefined algorithm.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> Based on the ITT population.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Gemcitabine/Paclitaxel</content>
                                    <br/>
                                    <content styleCode="bold">(N=267)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Paclitaxel</content>
                                    <br/>
                                    <content styleCode="bold">(N=262)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Time to Documented Disease Progression</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Median (95% CI) in months
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">5.2<br/>(4.2, 5.6)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">2.9<br/>(2.6, 3.7)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Hazard Ratio (95% CI)
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.650 (0.524, 0.805)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     p-value
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p&lt;0.0001
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Overall Survival</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Median (95% CI) in months
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">18.6<br/>(16.5, 20.7)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">15.8<br/>(14.1, 17.3)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Hazard Ratio (95% CI)<br/>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.86 (0.71, 1.04)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     p-value
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">Not Significant
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Overall Response Rate</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                    <br/>(95% CI)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">40.8% (34.9, 46.7)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">22.1% (17.1, 27.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     p-value
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p&lt;0.0001
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="fig2" styleCode="MultiMediaCaption">
                           <content styleCode="bold">Figure 2: Kaplan-Meier Curves for Time to Documented Disease Progression in Study 2</content>
                        </paragraph>
                        <renderMultiMedia ID="f03" referencedObject="mm03"/>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <observationMedia ID="mm03">
                           <text>Figure 2
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="gem0a-0007-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s83">
                     <id root="ca0db345-d64c-4ebf-855f-49524e06c301"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Non-Small Cell Lung Cancer
</title>
                     <text>
                        <paragraph>The efficacy of gemcitabine was evaluated in two randomized, multicenter trials.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s84">
                           <id root="5415541d-1ca0-4fc7-ba96-5a81cca3a441"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study 3: 28-Day Schedule</content>
                              </paragraph>
                              <paragraph>A multinational, randomized trial (Study 3) compared gemcitabine with cisplatin to cisplatin alone in the treatment of patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Patients were randomized to receive either gemcitabine 1,000 mg/m<sup>2</sup> on Days 1, 8, and 15 of each 28-day cycle with cisplatin 100 mg/m<sup>2</sup> on Day 1 after gemcitabine administration (N=260) or  cisplatin 100 mg/m<sup>2</sup> on Day 1 of each 28-day cycle (N=262). The major efficacy outcome measure was overall survival.
</paragraph>
                              <paragraph>A total of 522 patients were enrolled. Demographics and baseline characteristics (<linkHtml href="#t20">Table 20</linkHtml>) were similar between arms with the exception of histologic subtype of NSCLC, with 48% of patients on the cisplatin arm and 37% of patients on the gemcitabine with cisplatin arm having adenocarcinoma.
</paragraph>
                              <paragraph>Efficacy results are presented in <linkHtml href="#t21">Table 21</linkHtml> and <linkHtml href="#fig3">Figure 3</linkHtml>.
</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s85">
                           <id root="9e7bb417-b2e1-463c-a3bd-7074b087ce96"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study 4: 21-Day Schedule</content>
                              </paragraph>
                              <paragraph>A randomized (1:1), multicenter trial (Study 4) was conducted in patients with Stage IIIB or IV NSCLC. Patients were randomized to receive gemcitabine 1,250 mg/m<sup>2</sup> on Days 1 and 8 of each 21-day cycle with cisplatin 100 mg/m<sup>2</sup> on Day 1 after gemcitabine administration or etoposide 100 mg/m<sup>2</sup> intravenously on Days 1, 2, and 3 with cisplatin 100 mg/m<sup>2</sup> on Day 1 of each 21-day cycle. The major efficacy outcome measure was response rate.
</paragraph>
                              <paragraph>A total of 135 patients were enrolled. Demographics and baseline characteristics are summarized in <linkHtml href="#t20">Table 20</linkHtml>.
</paragraph>
                              <paragraph>Efficacy results are presented in <linkHtml href="#t21">Table 21</linkHtml>. There was no significant difference in survival between the two treatment arms. The median survival was 8.7 months for the gemcitabine with cisplatin arm versus 7 months for the etoposide with cisplatin arm. Median time to disease progression for the gemcitabine with cisplatin arm was 5 months compared to 4.1 months on the etoposide with cisplatin arm (Log rank p=0.015, two-sided). The objective response rate for the gemcitabine with cisplatin arm was 33% compared to 14% on the etoposide with cisplatin arm (Fisher's Exact p=0.01, two-sided).<br/>
                                 <br/>
                              </paragraph>
                              <paragraph ID="fig3" styleCode="MultiMediaCaption">
                                 <content styleCode="bold">Figure 3: Kaplan-Meier Curves for Overall Survival in Study 3</content>
                              </paragraph>
                              <renderMultiMedia ID="f04" referencedObject="mm04"/>
                              <table ID="t20" width="100%">
                                 <caption>Table 20: Baseline Demographics and Clinical Characteristics for Studies 3 and 4
</caption>
                                 <col width="19.284%" align="left"/>
                                 <col width="23.665%" align="left"/>
                                 <col width="11.402%" align="left"/>
                                 <col width="22.785%" align="left"/>
                                 <col width="22.865%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> N/A Not applicable.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Karnofsky Performance Status.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Trial</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">28-day Schedule (Study 3)</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">21-day Schedule (Study 4)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=260)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Cisplatin <br/>(N=262)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=69)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Etoposide/Cisplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=66)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Male
</td>
                                       <td align="center" valign="top" styleCode="Rrule">70%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">71%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">93%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">92%
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Median age, years
</td>
                                       <td align="center" valign="top" styleCode="Rrule">62
</td>
                                       <td align="center" valign="top" styleCode="Rrule">63
</td>
                                       <td align="center" valign="top" styleCode="Rrule">58
</td>
                                       <td align="center" valign="top" styleCode="Rrule">60
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Range
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">36 to 88
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">35 to 79
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">33 to 76
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">35 to 75
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Stage IIIA
</td>
                                       <td align="center" valign="top" styleCode="Rrule">7%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">7%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">N/A<sup>a</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">N/A<sup>a</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Stage IIIB
</td>
                                       <td align="center" valign="top" styleCode="Rrule">26%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">23%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">48%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">52%
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Stage IV
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">67%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">70%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">52%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">49%
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Lrule Rrule">Baseline KPS<sup>b</sup> 70 to 80<br/>
                                       </td>
                                       <td align="center" valign="top" styleCode="Rrule">41%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">44%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">45%
</td>
                                       <td align="center" valign="top" styleCode="Rrule">52%
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Baseline KPS<sup>b</sup> 90 to 100
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">57%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">55%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">55%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">49%
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t21" width="100%">
                                 <caption>Table 21: Efficacy Results for Studies 3 and 4
</caption>
                                 <col width="23.280%" align="left"/>
                                 <col width="22.420%" align="left"/>
                                 <col width="12.060%" align="left"/>
                                 <col width="22.420%" align="left"/>
                                 <col width="19.820%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> CI=confidence intervals.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> p-value two-sided Fisher's Exact test for difference in binomial proportions; log rank test for time-to-event analyses.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Trial</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">28-day Schedule (Study 3)</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">21-day Schedule (Study 4)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=260)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Cisplatin <br/>(N=262)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Gemcitabine/Cisplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=69)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Etoposide/Cisplatin</content>
                                          <br/>
                                          <content styleCode="bold">(N=66)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Survival</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Median (95% CI<sup>a</sup>) in months
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9.0 (8.2, 11.0)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.6 (6.6, 8.8)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.7 (7.8, 10.1)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.0 (6.0, 9.7)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     p-value<sup>b</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.008
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.18
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Time to Disease Progression</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Median (95% CI<sup>a</sup>) in months
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5.2 (4.2, 5.7)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.7 (3.0, 4.3)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5.0 (4.2, 6.4)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.1 (2.4, 4.5)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     p-value<sup>b</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.009
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.015
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Tumor Response</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">26%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">33%
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14%
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     p-value<sup>b</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p&lt;0.0001
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">p=0.01
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <observationMedia ID="mm04">
                           <text>Figure 3
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="gem0a-0007-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s86">
                     <id root="53cedeb5-53af-41c6-b553-c6244a623e88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Pancreatic Cancer
</title>
                     <text>
                        <paragraph>The efficacy of gemcitabine was evaluated in two trials (Studies 5 and 6), a randomized, single-blind, two-arm, active-controlled trial (Study 5) conducted in patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy and in a single-arm, open-label, multicenter trial (Study 6) conducted in patients with locally advanced or metastatic pancreatic cancer previously treated with fluorouracil or a fluorouracil-containing regimen. In Study 5, patients were randomized to receive either gemcitabine 1,000 mg/m<sup>2</sup> intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly for 3 consecutive weeks every 28-days in subsequent cycles (n=63) or fluorouracil  600 mg/m<sup>2</sup> intravenously over 30 minutes once weekly (n=63). In Study 6, all patients received gemcitabine 1,000 mg/m<sup>2</sup> intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly for 3 consecutive weeks every 28-days in subsequent cycles.
</paragraph>
                        <paragraph>The major efficacy outcome measure in both trials was “clinical benefit response”. A patient was considered to have had a clinical benefit response if either of the following occurred:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The patient achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a 20-point or greater improvement in performance status (Karnofsky Performance Status) for a period of at least 4 consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as 4 consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20-point decrease in performance status occurring during the first 12 weeks of therapy.
</item>
                        </list>
                        <paragraph>OR
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The patient was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation.
</item>
                        </list>
                        <paragraph>Study 5 enrolled 126 patients. Demographics and baseline characteristics were similar between the arms (<linkHtml href="#t22">Table 22</linkHtml>).
</paragraph>
                        <paragraph>The efficacy results are shown in <linkHtml href="#t23">Table 23</linkHtml> and <linkHtml href="#fig4">Figure 4</linkHtml>. Patients treated with gemcitabine had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to those randomized to receive fluorouracil. No confirmed objective tumor responses were observed in either treatment arm.
</paragraph>
                        <table ID="t22" width="100%">
                           <caption>Table 22: Baseline Demographics and Clinical Characteristics for Study 5
</caption>
                           <col width="37.767%" align="left"/>
                           <col width="31.600%" align="left"/>
                           <col width="30.633%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> Karnofsky Performance Status.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Gemcitabine</content>
                                    <br/>
                                    <content styleCode="bold">(N=63)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Fluorouracil</content>
                                    <br/>
                                    <content styleCode="bold">(N=63)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Male
</td>
                                 <td align="center" valign="top" styleCode="Rrule">54%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">54%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Median age
</td>
                                 <td align="center" valign="top" styleCode="Rrule">62 years
</td>
                                 <td align="center" valign="top" styleCode="Rrule">61 years
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Range
</td>
                                 <td align="center" valign="top" styleCode="Rrule">37 to 79
</td>
                                 <td align="center" valign="top" styleCode="Rrule">36 to 77
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Stage IV disease
</td>
                                 <td align="center" valign="top" styleCode="Rrule">71%
</td>
                                 <td align="center" valign="top" styleCode="Rrule">76%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Baseline KPS<sup>a</sup> ≤70
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">70%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">68%
</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t23" width="100%">
                           <caption>Table 23: Efficacy Results in Study 5
</caption>
                           <col width="37.767%" align="left"/>
                           <col width="31.600%" align="left"/>
                           <col width="30.633%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> p-value for clinical benefit response calculated using the two-sided test for difference in binomial proportions. All other p-values are calculated using log rank test.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Efficacy Parameter</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Gemcitabine</content>
                                    <br/>
                                    <content styleCode="bold">(N=63)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Fluorouracil</content>
                                    <br/>
                                    <content styleCode="bold">(N=63)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Clinical Benefit Response</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">22.2%
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">4.8%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     p-value<sup>a</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="middle" styleCode="Botrule Rrule">p=0.004
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Overall Survival</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule"/>
                                 <td align="center" valign="middle" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">     Median (95% CI) in months
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">5.7 (4.7, 6.9)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">4.2 (3.1, 5.1)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     p-value<sup>a</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="middle" styleCode="Botrule Rrule">p=0.0009
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Time to Disease Progression</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule"/>
                                 <td align="center" valign="middle" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Lrule Rrule">     Median (95% CI) in months
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">2.1 (1.9, 3.4)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">0.9 (0.9, 1.1)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     p-value<sup>a</sup>
                                 </td>
                                 <td colspan="2" align="center" valign="middle" styleCode="Botrule Rrule">p=0.0013
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="fig4" styleCode="MultiMediaCaption">
                           <content styleCode="bold">Figure 4: Kaplan-Meier Curves for Overall Survival in Study 5</content>
                        </paragraph>
                        <renderMultiMedia ID="f05" referencedObject="mm05"/>
                     </text>
                     <effectiveTime value="20241031"/>
                     <component>
                        <observationMedia ID="mm05">
                           <text>Figure 4
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="gem0a-0007-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s87">
               <id root="f7ce5b36-ddff-4857-9273-27c45ad55060"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES
</title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>“OSHA Hazardous Drugs.” OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
</item>
                  </list>
               </text>
               <effectiveTime value="20190904"/>
            </section>
         </component>
         <component>
            <section ID="s88">
               <id root="4fe4fa80-2537-424e-b882-3f28fb477247"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>Gemcitabine Injection is supplied as follows:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="18.827%" align="left"/>
                     <col width="32.549%" align="left"/>
                     <col width="48.624%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="justify" valign="top">
                              <content styleCode="bold">NDC</content>
                           </td>
                           <td align="justify" valign="top">
                              <content styleCode="bold">Gemcitabine Injection (38 mg per mL)</content>
                           </td>
                           <td align="justify" valign="top">
                              <content styleCode="bold">Package Factor</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="justify" valign="top">25021-239-05
</td>
                           <td align="justify" valign="top">200 mg per 5.26 mL Single-Dose Vial
</td>
                           <td align="justify" valign="top">1 vial per carton
</td>
                        </tr>
                        <tr>
                           <td align="justify" valign="top">25021-239-26
</td>
                           <td align="justify" valign="top">1 gram per 26.3 mL Single-Dose Vial
</td>
                           <td align="justify" valign="top">1 vial per carton
</td>
                        </tr>
                        <tr>
                           <td align="justify" valign="top">25021-239-52
</td>
                           <td align="justify" valign="top">2 grams per 52.6 mL Single-Dose Vial
</td>
                           <td align="justify" valign="top">1 vial per carton
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Gemcitabine Injection appears as a clear and colorless to light straw-colored solution.
</paragraph>
                  <paragraph>Store refrigerated between 2° and 8°C (36° and 46°F).
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not freeze.<br/>
                     </content>Discard unused portion.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile, Nonpyrogenic, Preservative-free.<br/>The container closure is not made with natural rubber latex.</content>
                  </paragraph>
                  <paragraph>Gemcitabine Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.<sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20200921"/>
            </section>
         </component>
         <component>
            <section ID="s89">
               <id root="f514800c-6c01-4212-8ccf-db9279c40fc6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="s90">
                     <id root="2263bdde-607c-40ec-8da9-f333dbff43a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Myelosuppression</content>
                        </paragraph>
                        <paragraph>Advise patients of the risks of myelosuppression. Instruct patients to immediately contact their healthcare provider should any signs or symptoms of infection, including fever, or if bleeding, or signs of anemia, occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="e90">
                     <id root="e114f08e-1dcb-48fd-b438-a152b7a14978"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Severe Cutaneous Adverse Reactions (SCARs)</content>
                        </paragraph>
                        <paragraph>Advise patients of the risks of SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Instruct patients to immediately contact their healthcare provider should any signs or symptoms of severe skin rash or skin peeling, blistering and/or mouth sores occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#e30">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s91">
                     <id root="3fd578c0-4d13-4109-9fb8-1dd9749ed071"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pulmonary Toxicity</content>
                        </paragraph>
                        <paragraph>Advise patients of the risks of pulmonary toxicity including respiratory failure and death. Instruct patients to immediately contact their healthcare provider for development of shortness of breath, wheezing, or cough <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s30">5.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s92">
                     <id root="027578aa-a36c-4b1e-b247-5de6ff555b71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hemolytic Uremic Syndrome and Renal Failure</content>
                        </paragraph>
                        <paragraph>Advise patients of the risks of hemolytic uremic syndrome and associated renal failure. Instruct patients to immediately contact their healthcare provider for changes in the color or volume of urine output or for increased bruising or bleeding <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s31">5.5</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s93">
                     <id root="56478424-16d5-4a89-b700-4cdd570714b7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatic Toxicity</content>
                        </paragraph>
                        <paragraph>Advise patients of the risks of hepatic toxicity including liver failure and death. Instruct patients to immediately contact their healthcare provider for signs of jaundice or for pain/tenderness in the right upper abdominal quadrant <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s32">5.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s94">
                     <id root="769b83a5-2144-4bf7-a4a5-5d0f80d65a13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise females and males of reproductive potential that gemcitabine can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment with gemcitabine and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with gemcitabine and for 3 months after the final dose <content styleCode="italics">[see Warnings and Precaution (<linkHtml href="#s33">5.7</linkHtml>), Use in Specific Populations (<linkHtml href="#s47">8.1</linkHtml>, <linkHtml href="#s53">8.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="s95">
                     <id root="c584e6dc-eaf3-47b7-8003-099e06f33ab1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with gemcitabine and for at least one week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s51">8.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190904"/>
                  </section>
               </component>
               <component>
                  <section ID="s96">
                     <id root="a4a93e01-41b7-435e-987e-d30abb32866a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise males of reproductive potential of the potential for reduced fertility with gemcitabine <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s53">8.3</linkHtml>), Nonclinical Toxicology (<linkHtml href="#s79">13.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>sagent<sup>®</sup>
                           <br/>Mfd. for SAGENT Pharmaceuticals<br/>Schaumburg, IL 60195 (USA)<br/>Made in India<br/>©2024 Sagent Pharmaceuticals
</paragraph>
                        <paragraph>Revised: October 2024
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s97">
               <id root="4d13c8d7-d6a9-4f65-87d8-c9ef12cfdbd1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</paragraph>
                  <paragraph>NDC 25021-239-05
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Gemcitabine Injection
</paragraph>
                  <paragraph>200 mg per 5.26 mL
</paragraph>
                  <paragraph>(38 mg per mL)
</paragraph>
                  <paragraph>For Intravenous Infusion Only
</paragraph>
                  <paragraph>Must Be Diluted Before Use
</paragraph>
                  <paragraph>Single-Dose Vial
</paragraph>
                  <paragraph>Discard unused portion
</paragraph>
                  <paragraph>Caution: Cytotoxic Agent
</paragraph>
                  <renderMultiMedia ID="f06" referencedObject="mm06"/>
               </text>
               <effectiveTime value="20250203"/>
               <component>
                  <observationMedia ID="mm06">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="gem0a-0007-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s98">
               <id root="ba6ef990-88d0-4985-8eb6-7ee4b4580f14"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</paragraph>
                  <paragraph>NDC 25021-239-26
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Gemcitabine Injection
</paragraph>
                  <paragraph>1 gram per 26.3 mL
</paragraph>
                  <paragraph>(38 mg per mL)
</paragraph>
                  <paragraph>For Intravenous Infusion Only
</paragraph>
                  <paragraph>Must Be Diluted Before Use
</paragraph>
                  <paragraph>Single-Dose Vial
</paragraph>
                  <paragraph>Discard unused portion
</paragraph>
                  <paragraph>Caution: Cytotoxic Agent
</paragraph>
                  <renderMultiMedia ID="f07" referencedObject="mm07"/>
               </text>
               <effectiveTime value="20250203"/>
               <component>
                  <observationMedia ID="mm07">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="gem0a-0007-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s99">
               <id root="671edc85-5f59-4966-8a62-a7caa6688458"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</paragraph>
                  <paragraph>NDC 25021-239-52
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Gemcitabine Injection
</paragraph>
                  <paragraph>2 grams per 52.6 mL
</paragraph>
                  <paragraph>(38 mg per mL)
</paragraph>
                  <paragraph>For Intravenous Infusion Only
</paragraph>
                  <paragraph>Must Be Diluted Before Use
</paragraph>
                  <paragraph>Single-Dose Vial
</paragraph>
                  <paragraph>Discard unused portion
</paragraph>
                  <paragraph>Caution: Cytotoxic Agent
</paragraph>
                  <renderMultiMedia ID="f08" referencedObject="mm08"/>
               </text>
               <effectiveTime value="20250203"/>
               <component>
                  <observationMedia ID="mm08">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="gem0a-0007-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>